Veritas In Silico Inc.(130A) News

SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter

The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS

Upgrading the Drug Discovery Platform ibVIS to aibVIS

Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline

Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio"

Company Presentation

Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction

Financial Results - Fiscal Year Ending December 2025, 3rd Quarter　

Non-consolidated Financial Results for the Nine Months Ended September 30, 2025 [Under Japanese GAAP]

[Summary] Financial Results for the Nine Months

Organizational Reforms and Personnel Changes

Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic

Revised Financial Forecast for FY2025

Relocation of the Shin-Kawasaki Research Institute

The Jikei University School of Medicine and VIS announce Start of Joint Research for Fundamentally Enhancing Therapeutic Effects of Pharmaceuticals

Nomination of a Candidate for Independent Outside Director

Non-consolidated Financial Results for the Six Months Ended June 30, 2025 [Under Japanese GAAP]

Financial Results - Fiscal Year Ended December 31, 2025, 2nd Quarter

Patent owned by Veritas In Silico receives Notice of Allowance in the U.S.

Mitsubishi Gas Chemical and VIS Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs